PIK3C2A and Decreased total leukocyte count: The main adverse events of almonertinib are elevation of CPK (19.6%), AST (12.3%), and ALT (11.4%), rash (12.7%), leukopenia (11.2%) and diarrhea (7.4%) [24], which are superior to other EGFR-TKIs.